These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 12381232)

  • 1. Danaparoid: a review of its use in thromboembolic and coagulation disorders.
    Ibbotson T; Perry CM
    Drugs; 2002; 62(15):2283-314. PubMed ID: 12381232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia.
    Wilde MI; Markham A
    Drugs; 1997 Dec; 54(6):903-24. PubMed ID: 9421696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Danaparoid sodium.
    Acostamadiedo JM; Iyer UG; Owen J
    Expert Opin Pharmacother; 2000 May; 1(4):803-14. PubMed ID: 11249517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Danaparoid in the prevention of thromboembolic complications.
    Skoutakis VA
    Ann Pharmacother; 1997; 31(7-8):876-87. PubMed ID: 9220051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Danaparoid for heparin-induced thrombocytopenia: an analysis of treatment failures.
    Kodityal S; Manhas AH; Udden M; Rice L
    Eur J Haematol; 2003 Aug; 71(2):109-13. PubMed ID: 12890149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness of danaparoid compared with enoxaparin as deep vein thrombosis prophylaxis after hip replacement surgery.
    Wade WE
    Am J Orthop (Belle Mead NJ); 1999 Apr; 28(4):229-31. PubMed ID: 10220094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients.
    Polkinghorne KR; McMahon LP; Becker GJ
    Am J Kidney Dis; 2002 Nov; 40(5):990-5. PubMed ID: 12407644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia.
    Tardy-Poncet B; Tardy B; Reynaud J; Mahul P; Mismetti P; Mazet E; Guyotat D
    Chest; 1999 Jun; 115(6):1616-20. PubMed ID: 10378558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The management of heparin-induced thrombocytopenia.
    Keeling D; Davidson S; Watson H;
    Br J Haematol; 2006 May; 133(3):259-69. PubMed ID: 16643427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of danaparoid sodium (danaparoid) on endotoxin-induced experimental disseminated intravascular coagulation (DIC) in rats.
    Fujishima Y; Yokota K; Sukamoto T
    Thromb Res; 1998 Sep; 91(5):221-7. PubMed ID: 9755834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ardeparin and danaparoid for prevention of deep vein thrombosis.
    Med Lett Drugs Ther; 1997 Oct; 39(1011):94-5. PubMed ID: 9379998
    [No Abstract]   [Full Text] [Related]  

  • 12. A comparison of danaparoid and warfarin for prophylaxis against deep vein thrombosis after total hip replacement: The Danaparoid Hip Arthroplasty Investigators Group.
    Comp PC; Voegeli T; McCutchen JW; Skoutakis VA; Trowbridge A; Overdyke WL
    Orthopedics; 1998 Oct; 21(10):1123-8. PubMed ID: 9801236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful use of danaparoid in treatment of heparin-induced thrombocytopenia during twin pregnancy.
    Gill J; Kovacs MJ
    Obstet Gynecol; 1997 Oct; 90(4 Pt 2):648-50. PubMed ID: 11770579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Danaparoid Sodium and Synthetic Protease Inhibitors for the Treatment of Disseminated Intravascular Coagulation Associated with Hematological Malignancies: A Retrospective Analysis.
    Minakata D; Fujiwara SI; Hayakawa J; Nakasone H; Ikeda T; Kawaguchi SI; Toda Y; Ito S; Ochi SI; Nagayama T; Mashima K; Umino K; Nakano H; Yamasaki R; Morita K; Kawasaki Y; Sugimoto M; Ishihara Y; Yamamoto C; Ashizawa M; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Ohmori T; Kanda Y
    Acta Haematol; 2020; 143(3):250-259. PubMed ID: 31461700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators.
    JAMA; 1998 Apr 22-29; 279(16):1265-72. PubMed ID: 9565006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heparin-induced thrombocytopenia (HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004.
    Magnani HN; Gallus A
    Thromb Haemost; 2006 Jun; 95(6):967-81. PubMed ID: 16732376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New treatment options for heparin-induced thrombocytopenia.
    Ortel TL; Chong BH
    Semin Hematol; 1998 Oct; 35(4 Suppl 5):26-34; discussion 35-6. PubMed ID: 9855181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. On the prophylactic and therapeutic use of danaparoid sodium (Orgaran) in patients with heparin-induced thrombocytopenia.
    Schenk JF; Pindur G; Stephan B; Mörsdorf S; Mertzlufft F; Kroll H; Wenzel E; Seyfert UT
    Clin Appl Thromb Hemost; 2003 Jan; 9(1):25-32. PubMed ID: 12643320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of 51 pregnancies with danaparoid because of heparin intolerance.
    Lindhoff-Last E; Kreutzenbeck HJ; Magnani HN
    Thromb Haemost; 2005 Jan; 93(1):63-9. PubMed ID: 15630492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heparin-induced thrombocytopenia-alternative anticoagulation in pregnancy and lactation.
    Lindhoff-Last E; Bauersachs R
    Semin Thromb Hemost; 2002 Oct; 28(5):439-46. PubMed ID: 12420239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.